Los betabloqueadores y su adecuado uso en pacientes con dislipidemia
Resumen
Los betabloqueadores y su adecuado uso en pacientes
con dislipidemia
Referencias
Oates JA, Brown NJ. Antihipertensores y fármaco-terapia de hipertensión. En: Hardman JG, Limbird LE. Goodman Gilman: las Bases farmacológicas de la terapéutica. 10ma ed. México: McGraw Hil; 2003. p. 881-910.
Yodú Ferral N. Fármacos que actúan sobre el siste-ma cardiovascular. Hipertensión arterial. En: Morón RodrÃguez FJ, Borroto Regalado R, Calvo Barbado DM, Cires Pujol M, Cruz Barrios MA, Fernández GarcÃa A, et al. FarmacologÃa clÃnica. La Habana: ECIMED; 2010. p. 1-34.
Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, et al. Effects of me-toprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol or metoprolol European Trial (COMET). Heart. 2007;93:8968-73.
Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24(7): 1397-403.
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalua-tion, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects
of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet. 2010;375(9718):906-15.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of euro-pean guidelines on hypertension management: a European Society of Hypertension Task Force docu-ment. J Hypertens. 2009;27(11):2121-58.
Shrivastava A, Gupta VB. Stability-Indicating RP-HPLC Method for the simultaneous determination of Prazosin, Terazosin, and Doxazosin in pharma-ceutical formulations. Sci Pharm. 2012;80(3):619-31.
De Backer G, Ambrosioni E, Borch-Johnsen K, Bro-tons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease pre-vention in clinical practice. European guidelines on cardiovascular disease prevention in clinical prac-tice. Eur J Cardio Prev Rev. 2003;10(4):S1-S10.
Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR, et al. Baseline heart rate, antihy-pertensive treatment, and prevention of cardio-vascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009; 54(13):1154-61.
Lavie CJ, Messerli FH, Milani RV. Beta-blockers as first-line antihypertensive therapy. The crumbling continues. J Am Coll Cardiol. 2009;54(13):1162-4.
Actualización en el tratamiento de la hipertensión arterial. BOLCAN [Internet]. 2011 [citado 5 Ene 2012];3(3):[aprox. 8 p.]. Disponible en:
http://www2.gobiernodecanarias.org/sanidad/scs/content/ee6b9302-a3cf-11e0-9610-f1717f4d08a3/bolcan_HTA_11.pdf
Los antagonistas de los receptores de angiotensina II (ARA-II) en el manejo de los pacientes hiperten-sos [Internet]. Santa Fe: Medicinapreventiva. Dis-ponible en:
http://www.medicinapreventiva.com.ve/articulos/antagonistas_de_los_receptores_de_angiotensina_II.htm
O’Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, DickerP, et al. Aliskiren reduces blood
pressure and suppresses plasma renin activity in combination with a thiazide diuretic, anangioten-sin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49(2):276-84.
Enlaces refback
- No hay ningún enlace refback.
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
